Feature

How to recognize and treat hidden inflammation


 

Glucocorticoids and immunosuppressants

Despite therapeutic intervention, the disease can have a fatal outcome, even if the patient is young, said Dr. Müller-Ladner. Glucocorticoids are the current therapy of choice. The dose is more than 0.5 mg of prednisolone equivalent per kg of body weight. “This usually leads to a rapid improvement in the inflammation. Subsequently, every organ is thoroughly diagnosed to assess the severity of the disease and to plan further treatment steps.”

In the long term, proven immunosuppressants, such as azathioprine, mycophenolate, leflunomide, and methotrexate, can be used, just as for many other chronic inflammatory diseases. Cyclophosphamide or cyclosporine is used more rarely, owing to their side effect profiles.

Because of the B-cell dominance, B-cell–depleting therapy with rituximab is currently a highly effective therapeutic option but one that must be applied for, because such use is off label. “If the body responds well to the medication, organ function often recovers,” said Dr. Müller-Ladner.

This article was translated from the Medscape German edition. A version appeared on Medscape.com.

Pages

Recommended Reading

Belimumab for pregnant women with lupus: B-cell concerns remain
MDedge Rheumatology
Best estimates made for hydroxychloroquine retinopathy risk
MDedge Rheumatology
Teamwork guides cardio-rheumatology clinics that care for unique patient population
MDedge Rheumatology
VEXAS syndrome: More common, variable, and severe than expected
MDedge Rheumatology
Topical CBD oil study suggests benefits for pain, healing in systemic sclerosis digital ulcers
MDedge Rheumatology
75 years: A look back on the fascinating history of methotrexate and folate antagonists
MDedge Rheumatology
Systemic sclerosis antibodies show link to interstitial lung disease in RA
MDedge Rheumatology
Two biomarkers identify high-risk lupus nephritis
MDedge Rheumatology
Health plans get very poor scores for access to autoimmune drugs
MDedge Rheumatology
New tool better estimates cardiovascular risk in people with lupus
MDedge Rheumatology